Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pseudoephedrine, Ephedrine Security Subject Of Upcoming DEA Rule

This article was originally published in The Tan Sheet

Executive Summary

The Drug Enforcement Administration expects to issue a proposed rule in June requiring pseudoephedrine, ephedrine and phenylpropanolamine handlers to follow certain security measures, according to the agency's 1"unified agenda" published in the Dec. 3 Federal Register

You may also be interested in...



OTC Distribution Channels Break Out With Prison Bureau Proposed Rule

Prison inmates will have expanded access to over-the-counter drug products under a Bureau of Prisons proposed rule published in the March 1 Federal Register.

OTC pseudoephedrine, PPA "ordinary" products subject to retail reporting threshold by DEA.

OTC PSEUDOEPHEDRINE, PPA "ORDINARY" PRODUCT RETAIL REPORTING THRESHOLD established under proposed implementing regulations to the Comprehensive Methamphetamine Control Act issued by the Drug Enforcement Administration and published in the Federal Register Oct. 7. Under the 1996 law, "ordinary" pseudoephedrine or phenylpropanolamine (PPA) products were exempt from the 24 g single transaction sales reporting trigger required for non-"ordinary" products. "Ordinary" products are defined in the act as those sold in packages not exceeding 3 g pseudoephedrine or PPA base and packaged in blister packs containing no more than two dosage units per blister.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel